{"organizations": [], "uuid": "0cb26f514e32d7339e0f202580f5839dfab8ce4a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-actobio-therapeutics-greenlighted/brief-actobio-therapeutics-greenlighted-by-fda-to-commence-a-phase-ib-iia-trial-with-ag019-idUSASC09U8G", "country": "US", "domain_rank": 408, "title": "BRIEF-Actobio Therapeutics Greenlighted By FDA To Commence A Phase Ib/Iia Trial With AG019", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-29T16:30:00.000+03:00", "replies_count": 0, "uuid": "0cb26f514e32d7339e0f202580f5839dfab8ce4a"}, "author": "", "url": "https://www.reuters.com/article/brief-actobio-therapeutics-greenlighted/brief-actobio-therapeutics-greenlighted-by-fda-to-commence-a-phase-ib-iia-trial-with-ag019-idUSASC09U8G", "ord_in_thread": 0, "title": "BRIEF-Actobio Therapeutics Greenlighted By FDA To Commence A Phase Ib/Iia Trial With AG019", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "north america", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "actobio therapeutics", "sentiment": "none"}, {"name": "intrexon corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29, 2018 / 1:31 PM / in 7 minutes BRIEF-Actobio Therapeutics Greenlighted By FDA To Commence A Phase Ib/Iia Trial With AG019 Reuters Staff 1 Min Read \nMarch 29 (Reuters) - Intrexon Corp: \n* ACTOBIO THERAPEUTICS GREENLIGHTED BY FDA TO COMMENCE A PHASE IB/IIA TRIAL WITH AG019 FOR THE TREATMENT OF EARLY ONSET TYPE 1 DIABETES \n* ACTOBIO THERAPEUTICS SAYS “SOON WILL START CLINICAL TRIALS” WITH AG019 “IN ASSOCIATION WITH SPECIALIZED INSTITUTES IN EUROPE AND NORTH AMERICA” Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-29T16:30:00.000+03:00", "crawled": "2018-03-29T16:52:57.073+03:00", "highlightTitle": ""}